Horizon Discovery enters into agreement with Roche Diagnostics
Horizon Discovery Group has entered into an agreement with Roche Diagnostics to assist in the development of immunohistochemistry (IHC) assays.
Pharmaceuticals, Biotechnology and Life Sciences
Horizon Discovery Group has entered into an agreement with Roche Diagnostics to assist in the development of immunohistochemistry (IHC) assays.
According to the press release from Thursday, Teva said it needs to reduce total cost base by $3 billion by the end…
Probably depends on where you live, and how the older folks trust the new machinery, but there are questions raised…
Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive topline results from a pivotal Phase 2 clinical study of…
Hikma Pharmaceuticals PLC (rated Ba1 Moody’s / BB+ S&P, both stable) has announced that its wholly-owned US subsidiary West-Ward Pharmaceuticals…
The board of directors of Eli Lilly and Company (NYSE: LLY) today announced an 8 percent increase in its quarterly…
Kite, a Gilead Company, announced updated results from the ongoing Phase 1/2 ZUMA-3 study of KTE-C19, a CD19 chimeric antigen…
Alexion Pharmaceuticals’s data from two Phase 1b/2 studies of ALXN1210, the company’s investigational long-acting C5 complement inhibitor, in patients with…
The U.S. Food and Drug Administration (FDA) said on Monday in an announcement that an adult smoking cessation education campaign…
Premaitha Health, a leading international molecular diagnostics group focused on non-invasive prenatal testing (NIPT), announces further expansion of its European…